相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study)
Hiroaki Akamatsu et al.
LUNG CANCER (2019)
Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma
Giuseppina Improta et al.
MEDICAL ONCOLOGY (2018)
Mechanisms of acquired resistance to afatinib clarified with liquid biopsy
Tomomi Nakamura et al.
PLOS ONE (2018)
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
Yi-Long Wu et al.
BRITISH JOURNAL OF CANCER (2017)
A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR)
Hiroaki Akamatsu et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
EGFR Mutation Subtypes Influence Survival Outcomes' following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients
Natalia Sutiman et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Multiplex Ultrasensitive Genotyping of Patients with Non-Small Cell Lung Cancer for Epidermal Growth Factor Receptor (EGFR) Mutations by Means of Picodroplet Digital PCR
Masaru Watanabe et al.
EBIOMEDICINE (2017)
Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor
Masahito Ogasawara et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
Masaru Watanabe et al.
CLINICAL CANCER RESEARCH (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer
Toshihiko Kaneda et al.
LUNG CANCER (2014)
Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients
Xuefei Li et al.
TRANSLATIONAL ONCOLOGY (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non-Small-Cell Lung Cancer
Victor H. F. Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Two Sides of the Same Coin: EGFR Exon 19 Deletions and Insertions in Lung Cancer
Katerina Politi et al.
CLINICAL CANCER RESEARCH (2012)
Clinical Outcomes in Non-Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR
Kuei-Pin Chung et al.
CLINICAL CANCER RESEARCH (2012)
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications
Antonio Marchetti et al.
PLOS ONE (2012)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
A. F. Gazdar
ONCOGENE (2009)
Structure and clinical relevance of the epidermal growth factor receptor in human cancer
Amit Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
Tetsuya Mitsudomi et al.
CANCER SCIENCE (2007)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
GJ Riely et al.
CLINICAL CANCER RESEARCH (2006)
Applications of Luminex (R) xMAP (TM) technology for rapid, high-throughput multiplexed nucleic acid detection
SA Dunbar
CLINICA CHIMICA ACTA (2006)
Mutations and addiction to EGFR:: the Achilles 'heal' of lung cancers?
AF Gazdar et al.
TRENDS IN MOLECULAR MEDICINE (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
分享论文
